This post was originally published on this site
Investing.com – Novavax stock (NASDAQ:NVAX) rose 2.5% Tuesday, a day after U.S. Centers for Disease Control and Prevention said that participants in the company’s late-stage Covid-19 vaccine trial can be considered fully vaccinated two weeks after completing their two-dose regimen.
The CDC said the guidance is not an endorsement of the shot, which is yet to be authorized for use in the country. Novavax expects to file for U.S. emergency use authorization by December.
The company has filed for regulatory authorization for its shot in India, Indonesia and the Philippines.
Novavax has repeatedly delayed regulatory filings and the timeline for ramping up production.
According to an August 5 Reuters report, the company is on track to submit a regulatory filing in the U.K. in September followed within weeks by submissions in Australia and Canada.
As per the Reuters report, Chief Executive Officer Stanley Erck said the company will produce 100 million doses per month in the current quarter and 150 million doses by the fourth quarter.
